Somahlution R&D Approach

Our patient-inspired R&D approach is grounded in a thoughtful focus on the real-world challenges that patients with damaged organs, and coronary or peripheral vascular disease face on a daily basis. Through this lens, we seek to develop new products and treatment options that offer significant clinical benefits, including improved patient health, safety and ease-of-use – all with the ultimate goal of improving patient outcomes for millions worldwide.

By identifying distinct areas of unmet clinical needs, we can identify unique therapeutic opportunities that can overcome treatment barriers and make a difference for patients.

In order to maximize product development opportunities, we tap into the full range of capabilities and expertise across the development continuum – from biology and chemistry innovation to clinical development, from engineering and development to commercialization. Because we design products specifically to address specific improvements in patient outcomes and with the user in mind, our products are distinctive within their markets.

Robust Product Pipeline

Our rich pipeline of product candidates demonstrates our leadership in product development for unmet clinical needs – an area where we have a proven track record. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients in the areas of ischemia reperfusion injury, organ and tissue transplantation, cardiothoracic and vascular surgery and renal dialysis.

Somahlution Clinical Trials

Somahlution’s clinical trials are important milestones on the path to discovering new products that may address significant unmet clinical needs for patients. Keeping physicians, patients and caregivers up-to-date about such studies is one of our top priorities.

For information about clinical trials using Somahlution’s products or development candidates, sponsored by Somahlution or other institutions, consult the National Institute of Health website, www.clinicaltrials.gov, which contains a searchable database.

Somahlution Investigator Initiated Trials

Somahlution seeks to support investigator research designed and conducted by independent physicians and scientists. Somahlution has supported numerous trials for vascular conduit and organ preservation. We have supported research in the US, Canada and Europe.

If you are interested in conducting an Investigator Initiated Trial, please contact Somahlution for further consideration.

Somahlution Medical Education Grants

Somahlution is committed to contributing to independent education (e.g. CME) through grants. Compliance with all applicable regulations and codes drives all activities and contributions of the company. Somahlution follows the requirements of the Compliance Program Guidance for Pharmaceutical Manufacturers issued by the Department of Health and Human Services Office of the Inspector General (“OIG Guidelines”), the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals (“PhRMA Code”), the FDA Guidance to Industry Supported Scientific and Educational Activities, and the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support.

During the current fiscal year, the company has assigned funds to support educational events in its areas of expertise and research. Somahlution provides educational grants only to support independent programs for interested healthcare participants where the program relates to therapies, disease states, or public health subjects in therapeutic areas in which Somahlution participates through its products or research.

Our particular focus this year includes educational activities with pragmatic approaches to improve patient care and public health in the domains of organ preservation. If you are interested in learning more, email us.